NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Earnings Put Its Valuation Back In Focus
Why Iovance Biotherapeutics stock is back in focus after Q2 earnings
Iovance Biotherapeutics (IOVA) drew fresh attention after reporting second quarter 2026 results, with revenue of $99.31 million and a narrower net loss, alongside a review of its full year revenue guidance of $350 million to $370 million.
See our latest analysis for Iovance Biotherapeutics.
Iovance Biotherapeutics stock has seen strong momentum build recently, with a 30 day share price return of 42% and a 1 year total...